Tuesday, Novartis AG (NYSE:NVS) received FDA approval for its Lutathera (lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for pediatric patients 12 years and older with somatostatin ...

While Lutathera was the first of its radionuclides to reach the market, Novartis’ flagship therapy is Pluvicto (lutetium lu177 vipivotide tetraxetan), which was approved by the FDA for PSMA ...

68 Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177 Lu-PSMA617 in 8 patients with PSA decline ? 98 percent in a prospective phase II study. Any disease ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

But there are other more specialist uses, such as using the radioactive Lutetium-177 isotope in cancer therapy. Lutetium ions were also used to dope gadolinium gallium garnet to make magnetic bubble ...

The device can produce short-lived medical isotopes such as Lu-177, Strontium-89 (Sr-89), and Yttrium-90 (Y-90) on a large scale, continuously and stably without the need to shut down the reactor.

During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual leading peptide-drug conjugate companies' market shares, challenges, ...